Day in Cordoba highlights the importance of a multidisciplinary approach to the fight against prostate cancer

The purpose of the meeting was to convey to society the importance early diagnosisemphasize the teamwork, interdisciplinarity, and cross-levels present in the approach to pathology and explain the research directions that are being developed.

The event, moderated by communicator Ana Espino, was attended by urologist Enrique Gómez, radiation oncologist Sonia García, medical oncologist Maria José Mendez and researcher Raúl Luque, as well as Carmen Fernández, psycho-oncologist from Cancer Association

.

The incidence of this tumor is more than one hundred cases per 100,000 inhabitants, it affects men over 50 years of age and is the most common tumor of solid organs in the world. male. In recent years, important advances have been made in its diagnosis and care.

This makes the approach increasingly complex and requires the recruitment of specialists in different areas so that the patient receives the most appropriate care, which includes primary care, UrologyRadiology, oncology Medical and radiation therapy, nuclear medicine and pathological anatomy.

Radiation oncologist Sonia Garcia assured that “this multidisciplinary approach is necessary to provide effective, personalized and patient-centered treatment. cooperation between specialists improves clinical outcomes and quality of life by ensuring all aspects are taken into account.

Proof

Urologist Enrique Gomez noted that although the tumor develops slowly and in most cases has a very high cure rate, “it still remains one of the main Causes of death

due to cancer in men.

Although there is no established health policy, as is the case with breast or colon cancer, “new data and advances in diagnostics are putting the proposal on the table to create realpolitik systematic early diagnosis.

In this sense, new studies are being developed that will provide evidence and help change clinical practice. “This is the case of the Prime Court and others like Providence who are studying the impact artificial intelligence in better predicting the prognosis of the disease,” says the urologist.

The number of patients with prostate cancer who can be enrolled in clinical trials is increasing. Dr. Mendez explained that “in recent years we have seen very important progress in systemic treatment against advanced disease

. “New treatments are being developed that target specific mutations in certain tumors, radiopharmaceuticals that selectively target tumor cells, and immunotherapeutic agents.”

Raoul Luquetresearcher from Imibic, spoke about the projects his team has worked on in recent years, funded by the Carlos III Institute of Health and the Ministry of Science and Innovation, focusing on the pathological connection between obesity and prostate cancer.